x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011779
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues at the carboxyl terminus of human ASM. Antibody was purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SMPD1 |
| UniProt No. | P17405 |
| Gene ID | 6609 |
| Gene Description | Sphingomyelinases catalyze the hydrolysis of sphingomyelin to produce ceramide and phosphocholine. Ceramide is an important bioactive lipid triggering signal transduction involved in cell proliferation, apoptosis and differentiation. A number of SMases have been described and categorized based on their optimum pH activity, cation dependence, tissue distribution, and subcellular localization. These include a lysosomal acid SMase, a Zn++-dependent secreted acid SMase, a membrane-bound Mg++-dependent neutral SMase, a Mg++-independent neutral SMase, and an alkaline SMase.Acid sphingomyelinase is a lysosomal enzyme responsible for the hydrolysis of sphingomyelin to ceramide and phosphocholine. The ASM gene encodes three proteins, ASM-1, ASM-2, and ASM-3, of which ASM-1 is the only catalytically active enzyme. ASM-1 can exist as a 70 kDa form as well as a 57 kDa proteoytic product. Expression of ASM is induced during monocytic cell differentiation. Defects in the ASM gene are associated with type A and type B Niemann-Pick disease. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
